Ofer Rotem

1.0k total citations
30 papers, 516 citations indexed

About

Ofer Rotem is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Ofer Rotem has authored 30 papers receiving a total of 516 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 22 papers in Pulmonary and Respiratory Medicine and 5 papers in Molecular Biology. Recurrent topics in Ofer Rotem's work include Lung Cancer Treatments and Mutations (17 papers), Lung Cancer Research Studies (14 papers) and Cancer Immunotherapy and Biomarkers (8 papers). Ofer Rotem is often cited by papers focused on Lung Cancer Treatments and Mutations (17 papers), Lung Cancer Research Studies (14 papers) and Cancer Immunotherapy and Biomarkers (8 papers). Ofer Rotem collaborates with scholars based in Israel, United States and Poland. Ofer Rotem's co-authors include Alona Zer, Elizabeth Dudnik, Tzippy Shochat, Nir Peled, Aaron M. Allen, Laila C. Roisman, Jair Bar, Mor Moskovitz, Damien Urban and Mira Wollner and has published in prestigious journals such as Annals of Oncology, International Journal of Cancer and Journal of Thrombosis and Haemostasis.

In The Last Decade

Ofer Rotem

27 papers receiving 513 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ofer Rotem Israel	11	379	312	113	99	84	30	516
R. Descourt France	13	364 1.0×	345 1.1×	78 0.7×	62 0.6×	18 0.2×	80	522
J.B. Auliac France	15	433 1.1×	604 1.9×	121 1.1×	161 1.6×	42 0.5×	64	741
Nobuyuki Katakami Japan	12	315 0.8×	485 1.6×	133 1.2×	133 1.3×	52 0.6×	26	621
Katia Dotti Italy	12	364 1.0×	149 0.5×	91 0.8×	56 0.6×	114 1.4×	28	514
Atsuto Mouri Japan	16	520 1.4×	385 1.2×	51 0.5×	43 0.4×	18 0.2×	72	677
Carina Hillenbach Switzerland	7	383 1.0×	319 1.0×	111 1.0×	65 0.7×	13 0.2×	11	630
Pauline du Rusquec France	10	225 0.6×	160 0.5×	93 0.8×	66 0.7×	23 0.3×	25	400
Jin‐Ji Yang China	13	316 0.8×	458 1.5×	138 1.2×	120 1.2×	44 0.5×	83	574
Guoqin Qiu China	10	203 0.5×	164 0.5×	76 0.7×	69 0.7×	12 0.1×	23	325
Kaoru Kaseda Japan	11	167 0.4×	255 0.8×	39 0.3×	53 0.5×	16 0.2×	38	390

Countries citing papers authored by Ofer Rotem

Since Specialization

Citations

This map shows the geographic impact of Ofer Rotem's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ofer Rotem with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ofer Rotem more than expected).

Fields of papers citing papers by Ofer Rotem

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ofer Rotem. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ofer Rotem. The network helps show where Ofer Rotem may publish in the future.

Co-authorship network of co-authors of Ofer Rotem

This figure shows the co-authorship network connecting the top 25 collaborators of Ofer Rotem. A scholar is included among the top collaborators of Ofer Rotem based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ofer Rotem. Ofer Rotem is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Dudnik, Elizabeth, I. Lavi, Ofer Rotem, et al.. (2025). The impact of brain MRI screening on stage IV NSCLC patients: A real world look at guidelines based care. Journal of the Neurological Sciences. 470. 123398–123398.

Tschernichovsky, Roi, Shlomit Yust‐Katz, Ofer Rotem, et al.. (2024). Converging survival trends in non-small cell lung cancer patients with and without brain metastasis receiving state-of-the-art treatment. Journal of Neuro-Oncology. 166(3). 461–469. 1 indexed citations

Tschernichovsky, Roi, Daniel A. Goldstein, Elizabeth Dudnik, et al.. (2023). Correlations between pathogenic variants in DNA repair genes and anticancer treatment efficacy in stage IV non‐small cell lung cancer: A large real‐world cohort and review of the literature. Thoracic Cancer. 14(17). 1589–1596. 3 indexed citations

Moskovitz, Mor, Sivan Shamai, Barliz Waissengrin, et al.. (2023). P2.07-09 Stage 3 NSCLC Patients Progressing After Concurrent Chemo-Radiotherapy and Durvalumab- is There a Role for Another IO?. Journal of Thoracic Oncology. 18(11). S327–S327. 1 indexed citations

Rotem, Ofer, Alona Zer, Einat Beery, et al.. (2023). Blood-Derived Exosomal hTERT mRNA in Patients with Lung Cancer: Characterization and Correlation with Response to Therapy. Biomedicines. 11(6). 1730–1730. 3 indexed citations

Zer, Alona, Mojca Unk, Pilar Garrido, et al.. (2023). 1488P Exploring efficacy and safety of immune checkpoint inhibitors (ICI) in extensive stage (ES)- small-cell lung cancer (SCLC) in specific populations: Real-world data from the Durvalumab Expanded Access program Regional European cohort (DEAR). Annals of Oncology. 34. S840–S840.

Shimony, Shai, Tzippy Shochat, Galia Spectre, et al.. (2021). Venous thromboembolism incidence and risk assessment in lung cancer patients treated with immune checkpoint inhibitors. Journal of Thrombosis and Haemostasis. 19(5). 1250–1258. 54 indexed citations

Rotem, Ofer, et al.. (2021). The Relationship of Diabetes Mellitus to Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung Cancer. Oncology. 99(9). 555–561. 20 indexed citations

Kuchuk, Iryna, Tzippy Shochat, Aarón Sulkes, et al.. (2021). Taxane versus vinorelbine in combination with trastuzumab and pertuzumab for first-line treatment of metastatic HER2-positive breast cancer: a retrospective two-center study. Breast Cancer Research and Treatment. 188(2). 379–387. 2 indexed citations

10.

Dudnik, Elizabeth, Jair Bar, Assaf Moore, et al.. (2021). BAP1-Altered Malignant Pleural Mesothelioma: Outcomes With Chemotherapy, Immune Check-Point Inhibitors and Poly(ADP-Ribose) Polymerase Inhibitors. Frontiers in Oncology. 11. 603223–603223. 14 indexed citations

11.

Domachevsky, Liran, David Groshar, Elizabeth Dudnik, et al.. (2020). Lower tumor volume is associated with increased benefit from immune checkpoint inhibitors in patients with advanced non‐small‐cell lung cancer. Asia-Pacific Journal of Clinical Oncology. 17(2). e125–e131. 4 indexed citations

12.

Rotem, Ofer, et al.. (2020). Efficacy of immune check-point inhibitors (ICPi) in large cell neuroendocrine tumors of lung (LCNEC). Lung Cancer. 143. 40–46. 37 indexed citations

13.

Dudnik, Elizabeth, Mor Moskovitz, Abed Agbarya, et al.. (2020). Alternative nivolumab duration and scheduling in advanced nonsmall cell lung cancer: A real‐world evidence. International Journal of Cancer. 148(5). 1183–1191. 1 indexed citations

14.

Dudnik, Elizabeth, Aaron M. Allen, Tzippy Shochat, et al.. (2020). Stereotactic Radiosurgery for Brain Metastases in Small Cell Lung Cancer: The Davidoff Cancer Center Experience.. PubMed. 22(1). 22–26. 4 indexed citations

15.

Peled, Nir, et al.. (2019). Circulating Tumor DNA T790M Testing as a Predictor of Osimertinib Efficacy in Epidermal Growth Factor Receptor Mutant Non-small Cell Lung Cancer: A Single Center Experience.. PubMed. 21(6). 394–398. 1 indexed citations

16.

Dudnik, Elizabeth, Mor Moskovitz, Abed Agbarya, et al.. (2019). OA11.06 Alternative Nivolumab (N) Duration and Scheduling in Advanced Non-Small Cell Lung Cancer (aNSCLC): Real-Life Data. Journal of Thoracic Oncology. 14(10). S235–S236. 6 indexed citations

17.

Peled, Nir, Moshe Mishaeli, Tzippy Shochat, et al.. (2019). Efficacy and Safety of ALK Tyrosine Kinase Inhibitors in Elderly Patients with Advanced ALK-Positive Non-Small Cell Lung Cancer: Findings from the Real-Life Cohort. Oncology Research and Treatment. 42(5). 275–282. 8 indexed citations

18.

Peled, Nir, et al.. (2018). P3.04-28 Can Ipilimumab Restore Immune Response in Advanced NSCLC After Progression on Anti PD1/PDL1 Agents?. Journal of Thoracic Oncology. 13(10). S932–S932. 1 indexed citations

19.

Peled, Nir, Ofer Rotem, Hovav Nechushtan, et al.. (2018). P2.01-02 Osimertinib for EGFR-Positive Advanced NSCLC with Brain Metastases: Preliminary Analysis of an Open-Label, Two-Arm, Phase 2 Study. Journal of Thoracic Oncology. 13(10). S665–S666. 1 indexed citations

20.

Dvir, Addie, Lior Soussan‐Gutman, Maya Ilouze, et al.. (2018). The Clinical Impact of Comprehensive Genomic Testing of Circulating Cell-Free DNA in Advanced Lung Cancer. Journal of Thoracic Oncology. 13(11). 1705–1716. 40 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact